ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pregnancy"

  • Abstract Number: 1352 • ACR Convergence 2023

    Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study

    Yanint Raksadawan1, Aravind Polam1, Nattanicha Chaisrimaneepan2 and Sabahat Usmani1, 1Weiss Memorial Hospital, Chicago, IL, 2Texas Tech University Health Sciences, Lubbock, TX

    Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis which affects women of reproductive age. There is limited information about the effect of TA on…
  • Abstract Number: 2292 • ACR Convergence 2023

    Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?

    Dina Zucchi1, Giancarlo Cascarano2, Antonio Collesei3, Elena Elefante2, Francesca Monacci4, Chiara Ietto4, Linda Carli2, Sabrina Gori2, Valentina Gelsi4, Chiara Tani2 and Marta Mosca2, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy, 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 3Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Familial Cancer Clinics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy, 4Department of Clinical and Experimental Medicine, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy

    Background/Purpose: Systemic Lupus Erythematosus (SLE) patients are at risk of disease flare during pregnancy; risk stratification is crucial for personalized treatment and monitoring. Our hypothesis…
  • Abstract Number: 0476 • ACR Convergence 2023

    Factors Associated with the Need for Assisted Reproductive Therapies in a Spanish Cohort of Patients with Rheumatic Diseases

    Antía García-Fernández1, Fernando Rengifo-García1, Raquel Senosiain-Echarte1, Miguel álvaro-Navidad1, Miguel A Gonzalez-Gay2 and Juan A Martínez-López1, 1Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 2IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain

    Background/Purpose: Patients with rheumatic diseases (RMD) have a lower pregnancy rate, with infertility being one of the main causes. The rate of assisted reproductive therapies…
  • Abstract Number: 1354 • ACR Convergence 2023

    The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus

    Ceshae Harding1, Amanda Eudy2, Catherine Sims1, Cuoghi Edens3, Mehret Birru Talabi4, Rosalind Ramsey-Goldman5, Laura Neil1 and Megan Clowse6, 1Duke University, Durham, NC, 2Duke University, Raleigh, NC, 3University of Chicago, Chicago, IL, 4University of Pittsburgh, Pittsburgh, PA, 5Northwestern University, Chicago, IL, 6Duke University, Chapel Hill, NC

    Background/Purpose: Mental health conditions are the leading cause of maternal mortality across most of the United States. Among individuals with SLE, pregnancy intention has been…
  • Abstract Number: 2305 • ACR Convergence 2023

    Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus

    Dr Hiba Khogali1, Ghada Al‐Bluwi2, Virgie Guy2 and Ali Al Dhanhani3, 1Tawam Hospital, Al Ain, United Arab Emirates, 2College of Medicine, UAE University, Al Ain, United Arab Emirates, 3UAE University, Al Ain, United Arab Emirates

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…
  • Abstract Number: L13 • ACR Convergence 2022

    Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block

    Stephanie Benjamin1, Lisa Vi2, Diptendu Chatterjee1, Edgar Jaeggi1, Marie Wahren-Herlenius3, Amelia Ruffatti4, Linda Hiraki5, Michelle Lohbihler2, Lusia Sepiashvili1, Carl Laskin6, Meena Fatah1, Daniela Dominguez5, Lawrence Ng5, Anthony Gramolini2, Vincent Christoffels7, Stephanie Protze2 and Robert Hamilton8, 1Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 4Universitå di Padova, Padova, Italy, 5The Hospital for Sick Children, Toronto, ON, Canada, 6Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, 7Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, 8Hospital for Sick Children, Markham, ON, Canada

    Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
  • Abstract Number: 0946 • ACR Convergence 2022

    The Impact of Pregnancy Planning and Medical Readiness on Reproductive Outcomes in Women with SLE

    Catherine Sims1, Amanda Eudy2, Jayanth Doss1, Lisa Criscione-Schreiber3, Kai Sun3, Rebecca Sadun1, Jennifer L Rogers4 and Megan Clowse1, 1Duke University, Durham, NC, 2Duke University, Raleigh, NC, 3Duke University School of Medicine, Durham, NC, 4Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC

    Background/Purpose: The ACR Reproductive Health Guidelines recommend that a woman conceive when her SLE is quiescent, she is not taking a teratogenic medication, and that…
  • Abstract Number: 0963 • ACR Convergence 2022

    Exploring Reasons for Non-Use of Hydroxychloroquine in SLE Pregnancy

    Antonia Chan1, Alanna Hirz1, Yashaar Chaichian1, Amadeia Rector2, Maurice Druzin3 and Julia Simard2, 1Stanford University, Stanford, CA, 2Stanford University School of Medicine, Palo Alto, CA, 3Stanford University School of Medicine, Palo Alto

    Background/Purpose: Although hydroxychloroquine (HCQ) is strongly recommended in systemic lupus (SLE) pregnancy, the percentage of pregnant patients with SLE taking HCQ appears highly variable across…
  • Abstract Number: 0947 • ACR Convergence 2022

    Development of a Person-Centered Family Planning Decision Aid for Women with Rheumatic Diseases

    Mehret Birru Talabi1, Traci Kazmerski2, Raelynn O'Leary3, Ashley Deal3, Megan Clowse4, Oilvia Stransky5 and Sonya Borrero5, 1University of Pittsburgh, Pittsburgh, PA, 2Children's Hospital of Pittsburgh, Pittsburgh, 3Carnegie Mellon University School of Design, Pittsburgh, 4Duke University, Durham, NC, 5University of Pittsburgh, Pittsburgh

    Background/Purpose: Given the potential for pregnancy-associated mortality and morbidity, the question of whether and/or when to become pregnant is often a profoundly important decision for…
  • Abstract Number: 0964 • ACR Convergence 2022

    High Rates of Fetal Growth Restriction in Systemic Lupus Erythematosus Pregnancies

    Raeann Whitney, Sarah Green, Alex Camai, Ashley Suh, Katherine Walker, Wheless Lee and April Barnado, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Fetal growth restriction (FGR) and small for gestational age (SGA) are associated with increased perinatal morbidity and mortality. While Systemic lupus erythematosus (SLE) increases…
  • Abstract Number: 0948 • ACR Convergence 2022

    Fertility and the Use of Assisted Reproductive Technologies: Perceptions, Thoughts and Experiences of Men and Women with Rheumatic Disease

    Emily Peninger1, Molly Leavitt1, Cuoghi Edens1 and Shilpa Venkatachalam2, 1University of Chicago, Chicago, IL, 2Global Healthy Living Foundation, New York, NY

    Background/Purpose: Patients with rheumatic diseases have fewer biologic children than those without for a number of reasons, including infertility. Patients with rheumatic diseases may therefore…
  • Abstract Number: 0965 • ACR Convergence 2022

    Pregnancy Outcomes in a Diverse Lupus Cohort

    Julia Simard1, Emily Liu2, Eliza Chakravarty3, Amadeia Rector1, Miranda Cantu4, Daniel Kuo5, Gary Shaw6, Maurice Druzin6, Michael Weisman7 and Monique Hedderson2, 1Stanford University School of Medicine, Palo Alto, CA, 2Kaiser Permanente Northern California’s Division of Research, Oakland, CA, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Global Lupus Support Group, Portage, MI, 5Kaiser Permanente, Redwood City Medical Center, Redwood City, CA, 6Stanford University School of Medicine, Palo Alto, 7Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA

    Background/Purpose: Although the overall systemic lupus (SLE) patient population is racially and ethnically diverse, many study populations are homogeneous. We assembled a diverse group of…
  • Abstract Number: 0949 • ACR Convergence 2022

    Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience

    Joo Young (Esther) Lee1, Arielle Mendel2, Anca Askanase3, Sang-Cheol Bae4, Jill Buyon5, Ann E Clarke6, Nathalie Costedoat-Chalumeau7, Paul R Fortin8, Dafna Gladman9, John Hanly10, Murat Inanc11, David Isenberg12, Anselm Mak13, Marta Mosca14, Michelle Petri15, Anisur Rahman16, Rosalind Ramsey-Goldman17, Jorge Sanchez-Guerrero18, Murray Urowitz19, Daniel Wallace20, Sasha Bernatsky21 and Evelyne Vinet2, 1McGill University, Montréal, QC, Canada, 2McGill University Health Centre, Montréal, QC, Canada, 3Columbia University Medical Center, New York, NY, 4Hanyang University Medical Center, Seoul, Republic of Korea, 5NYU Grossman School of Medicine, New York, NY, 6University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 7Inserm DR Paris 5, Paris, France, 8Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, 9Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 10Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, 11Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, 12University College London, London, United Kingdom, 13Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 14Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 15Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 16Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 17Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 18Sinai Health System, Toronto, ON, Canada, 19University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 20Cedars-Sinai Medical Center, Los Angeles, CA, 21Research Institute of the McGill University Health Centre, Montréal, QC, Canada

    Background/Purpose: One-third of women with SLE develop lupus nephritis (LN), and most receive mycophenolate mofetil (MMF). However, MMF is teratogenic, and needs to be switched…
  • Abstract Number: 0966 • ACR Convergence 2022

    Assessment and Application of Royal College of Obstetricians and Gynaecologists (RCOG) Risk Scores in the Prevention of Venous Thromboembolism Peri- and Postpartum in Systemic Lupus Erythematosus

    Alexis Engel1, Myah Griffin2, Michael Golpanian2, Julie Nusbaum3, Peter Izmirly4, Michael Belmont4, Shilpi Mehta-Lee2 and Jill Buyon4, 1New York University School of Medicine, New York, NY, 2NYU Langone Health, New York, NY, 3NYU Long Island School of Medicine, Mineola, NY, 4NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Patients with SLE may be at increased risk for developing a venous thromboembolism (VTE), particularly in the postpartum period. The Royal College of Obstetricians…
  • Abstract Number: 0950 • ACR Convergence 2022

    Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry

    Sinead Maguire1, Samar Al emadi2, Paul Alba3, Mathia C Aguiar4, Talal Al Lawati5, Gelsomina Alle6, Bonnie Bermas7, Suleman Bhana8, Branimir Anic9, Inita Bulina10, Megan Clowse11, Adriana Karina Cogo12, Iris Colunga13, Claire Cook14, KAREN JOYCE CORTEZ15, Kathryn Dao16, Milena Gianfrancesco17, Monique Gore-Massy18, Laure Gossec19, Rebecca Grainger20, Jonathan Hausmann21, Tiffany YT Hsu22, Kimme Hyrich23, Carolina Isnardi24, Yumeko Kawano22, Rachael Kilding25, Daria A Kusevich26, Saskia Lawson-Tovey27, Jean Liew28, Eoghan McCarthy29, Anna Montgomery30, Sebastian Moyano3, Noreen Nasir31, IVAN PADJEN32, Charalampos Papagoras33, Naomi Patel34, MARIANA PERA35, Cecilia Pisoni36, Guillermo Pons-Estel37, Antonio Lorenzo Quiambao38, Rosana Quintana39, Eric Ruderman40, Sebastian Sattui41, Veronica Savio42, Savino Sciascia43, Marieta Sencarova44, Rosa Serrano-Morales45, Faizah Siddique46, Emily Sirotich47, Jeffrey Sparks48, Anja Strangfeld49, Paul Sufka50, Helen Tanner51, Yohana Tissera52, Zachary Wallace14, Marina Werner53, Leanna Wise54, Angus Worthing55, JoAnn Zell56, Julija Zepa10, Pedro Machado57, Jinoos Yazdany17, Philip Robinson51 and Richard Conway1,1St James' Hospital, Dublin, Ireland, 2Hamad Medical Corporation, Doha, Qatar, 3Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Hospital General Agustin O`Horan, Merida, Mexico, 5Sultan Qaboos University Hospital, Muscat, Oman, 6Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 7UT Southwestern, Dallas, TX, 8Crystal Run Healthcare, Middletown, NY, 9Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, 10Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, 11Duke University, Durham, NC, 12Hospital Interzonal Luis Guemes, Haedo and Hospital San Juan de Dios, Castelar, Buenos Aires, Argentina, 13Hospital Universitario UANL, Monterrey, Mexico, 14Massachusetts General Hospital, Boston, MA, 15Baguio General Hospital Medical Center, Baguio, Philippines, 16UT Southwestern Medical Center, Dallas, TX, 17University of California San Francisco, San Francisco, CA, 18Covid-19 GRA, West Orange, NJ, 19Sorbonne Université, Paris, France, 20University of Otago, Wellington, New Zealand, 21Division of Immunology, Boston Children's Hospital, Boston, MA, 22Brigham and Women's Hospital, Boston, MA, 23The University of Manchester, Manchester, United Kingdom, 24SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 25Sheffield teaching hospitals trust, Sheffield, United Kingdom, 26VA Nasonova Research Institute of Rheumatology, Moscow and Anikina Clinic, Vidnoe, Russia, 27Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 28Boston University, Boston, MA, 29Beaumont Hospital, Dublin, Ireland, 30University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, 31Aga Khan University Hospital, Karachi Pakistan, Karachi, Pakistan, 32University Hospital Center Zagreb, Zagreb, Croatia, 33First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, 34Massachusetts General Hospital, Sale Creek, TN, 35Hospital Ángel C Padilla, San Miguel de Tucumán, Tucuman, Argentina, 36CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, 37Argentine Society of Rheumatology, Buenos Aires, Argentina, 38East Avenue Medical Center, Quezon City, Philippines, 39Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 40Northwestern University Feinberg School of Medicine, Chicago, IL, 41University of Pittsburg, Pittsburg, Pennsylvania, USA, PIttsburgh, PA, 42Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, 43University of Turin, Torino, Italy, 44Univerzitna nemocnica L Pasteura, Slovakia, Kosice, Slovakia, 45Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, 46Loyola University Medical Center, Elmhurst, IL, 47Department of Health Research, Evidence and Impact, McMaster University, Hamilton, ON, Canada, 48Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 49Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 50HealthPartners, Eagan, MN,51University of Queensland School of Medicine, Brisbane, Queensland, Australia, 52Internal Medicine Service, Rheumatology Unit, Hospital Córdoba y Sanatorio Parque de Córdoba, Córdoba, Argentina, 53Hospital Nacional de Clínicas, Córdoba, Argentina, 54LAC+USC/Keck Medicine of USC, Pasadena, CA, 55Arthritis & Rheumatism Associates, PC, Washington, DC, 56University of Colorado Anschutz Medical Campus, Aurora, CO, 57Centre for Rheumatology & Department of Neuromuscular Diseases, University College London and National Institute for Health Research (NIHR), University College London Hospitals NHS Foundation Trust, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom

    Background/Purpose: To describe obstetric outcomes based on COVID-19 vaccination status in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.Methods: We extracted…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology